Sandbox:Fixed Drug eruption

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]

Synonyms and keywords:

## Overview[edit | edit source]

## Historical Perspective[edit | edit source]

Patient Information

TAGRISSO™ (tuh-GRISS-oh)

(osimertinib)

tablet

What is the most important information I should know about Osimertinib?

Osimertinib may cause serious side effects, including:

lung problems. Osimertinib may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.

heart problems, including heart failure. Osimertinib may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking Osimertinib and during treatment. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded.

See “What are the possible side effects of Osimertinib?” for more information about side effects.

What is Osimertinib?

Osimertinib is a prescription medicine used to treat non-small cell lung cancer (NSCLC). Osimertinib may be used when your non-small cell lung cancer has spread to other parts of the body and:

has a certain type of abnormal epidermal growth factor receptor (EGFR) gene, called T790M, and

you have had previous treatment with an EGFR tyrosine kinase inhibitor medicine and it has stopped working.

Your doctor will perform a test to make sure that Osimertinib is right for you.

It is not known if Osimertinib is safe and effective in children.

Before taking Osimertinib, tell your doctor about all of your medical conditions, including if you:

have lung or breathing problems

have heart problems, including a condition called long QTc syndrome

have problems with your electrolytes, such as sodium, potassium, calcium or magnesium

are pregnant or plan to become pregnant. Osimertinib can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with Osimertinib or think you may be pregnant.

Females who are able to become pregnant should use an effective birth control during treatment with Osimertinib and for 6 weeks after the final dose of Osimertinib.

Males who have female partners that are able to become pregnant should use effective birth control during treatment with Osimertinib and for 4 months after the final dose of Osimertinib.

are breastfeeding or plan to breastfeed. It is not known if Osimertinib passes into your breast milk. Do not breastfeed during treatment with Osimertinib and for 2 weeks after your final dose of Osimertinib. Talk to your doctor about the best way to feed your baby during this time.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine.

How should I take Osimertinib?

Take Osimertinib exactly as your doctor tells you to take it.

Your doctor may change your dose, temporarily stop, or permanently stop treatment with Osimertinib if you have side effects.

Take Osimertinib 1 time each day.

You can take Osimertinib with or without food.

If you miss a dose of Osimertinib, do not make up for the missed dose. Take your next dose at your regular time.

If you cannot swallow Osimertinib tablets whole:

place your dose of Osimertinib in a container that contains 60 mL (2 ounces) of water. Do not use carbonated water or any other liquids.

stir the Osimertinib tablet and water until the Osimertinib tablet is in small pieces (the tablet will not completely dissolve). Do not crush, heat, or use ultrasound to prepare the mixture.

drink the Osimertinib and water mixture right away.

add 120 mL to 240 mL (4 to 8 ounces) of water into the container and drink to make sure that you take your full dose of Osimertinib.
What are the possible side effects of Osimertinib?

Osimertinib may cause serious side effects, including:

See “What is the most important information I should know about Osimertinib?”

The most common side effects of Osimertinib are:

diarrhea

rash

dry skin

changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Osimertinib. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Osimertinib?

Store Osimertinib at room temperature between 68°F to 77°F (20°C to 25°C).

Safely throw away medicine that is out of date or that you no longer need.

Keep Osimertinib and all medicines out of the reach of children.
General information about the safe and effective use of Osimertinib.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Osimertinib for a condition for which it was not prescribed. Do not give Osimertinib to other people, even if they have the same symptoms you have. It may harm them. You can ask your doctor or pharmacist for information about Osimertinib that is written for a health care professional.
What are the ingredients in Osimertinib?

Active ingredient: osimertinib

Inactive ingredients: mannitol, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and sodium stearyl fumarate. Tablet coating contains: polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, ferric oxide yellow, ferric oxide red and ferric oxide black.

For more information, go to www.Osimertinib.com or call 1-800-236-9933.

Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

©AstraZeneca 2015

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: August 2016

## Classification[edit | edit source]

## Pathophysiology[edit | edit source]

## Epidemiology and Demographics[edit | edit source]

## Screening[edit | edit source]

## Natural History, Complications, and Prognosis[edit | edit source]

### Natural history[edit | edit source]

### Complications[edit | edit source]

### Prognosis[edit | edit source]

## Diagnosis[edit | edit source]

### History and symptoms[edit | edit source]

### Physical examination[edit | edit source]

### Laboratory findings[edit | edit source]

## Treatment[edit | edit source]

### General measures[edit | edit source]

Good hygiene which include retracting the foreskin regularly and gentle cleansing of entire glans, preputial sac, and foreskin were found effective in treating the diseases.

### Medical Therapy[edit | edit source]

### Surgery[edit | edit source]

### Photodynamic therapy[edit | edit source]

### Miscellaneous therapies[edit | edit source]

## Prevention[edit | edit source]

### Primary Prevention[edit | edit source]

### Secondary prevention[edit | edit source]

## References[edit | edit source]